How Mounjaro works for weight loss — and why the evidence matters

What the trial data actually showed, and why two receptors outperform one

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and no diabetes, randomising them to tirzepatide at 5mg, 10mg or 15mg, or placebo, over 72 weeks. At the 15mg dose, average body-weight reduction reached roughly 20–21%. That figure put tirzepatide meaningfully ahead of semaglutide 2.4mg in subsequent head-to-head data from the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which found tirzepatide produced greater average weight loss in a direct comparison over the same duration.

The reason for that gap lies in the dual mechanism. GLP-1 receptor agonists (the class that includes semaglutide) slow gastric emptying and reduce appetite by acting on the brain's satiety centres. Tirzepatide does all of that, but also activates GIP receptors. GIP is a gut hormone released after eating; stimulating its receptor appears to deepen the satiety signal and may influence how the body handles fat stores. The combination produces a stronger and more sustained reduction in calorie intake than either pathway alone.

This is not simply about feeling less hungry in the short term. NHS guidance on tirzepatide describes it as a medicine for weight management alongside a reduced-calorie diet and increased activity, the lifestyle component matters because the hormonal signals work best when supported by behaviour, not as a substitute for it. Understanding what tirzepatide is and how it differs from other GLP-1 medicines helps explain why its results stand apart from earlier options.

How the appetite and gastric signals translate into real-world weight change

Gastric emptying is the pace at which food moves from the stomach into the small intestine. Slow it down and the stomach stays fuller for longer after a meal, which means the signal to eat again arrives later. That single effect can substantially reduce daily calorie intake without the person making a conscious effort to eat less, they simply find they are satisfied with smaller portions.

Layered on top of this is central appetite suppression. Tirzepatide acts on receptors in the hypothalamus, the brain region that governs hunger and energy balance. The result is a reduction in appetite between meals, not just a sensation of fullness after eating. People often describe a quietening of what clinicians sometimes call food noise, the persistent preoccupation with eating that many people with obesity experience.

Weight loss, then, is the downstream outcome of several signals converging: slower gastric emptying, reduced appetite, lower calorie intake, and (over time) a recalibration of the body's defended weight. That last point matters. Obesity involves biological mechanisms, not a failure of willpower, and if you want to understand how Mounjaro works to produce weight loss through these physiological pathways, that detail is worth reading before a consultation. If you want to understand exactly how Mounjaro causes weight loss at a physiological level, that detail is worth reading before a consultation.

A practical habit worth building before any appointment: check that your pharmacy is registered by searching the GPhC register, it takes under a minute and confirms you are dealing with a regulated dispensing service.

Eligibility, the titration schedule, and what happens when the dose increases

The UK licence covers adults with a BMI of 30 or above, or 27 and above if at least one weight-related condition is present, conditions such as hypertension, high cholesterol, type 2 diabetes, prediabetes or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not determine whether treatment is right for you; a prescriber considers your full medical picture.

Titration is the process of moving through doses over time. Treatment starts at 2.5mg, this dose exists so your body can adapt to the medicine's effects on gastric emptying before the therapeutic doses begin. The prescriber then steps the dose upward, typically every four weeks, through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg. Not everyone reaches the maximum; some people respond well at an intermediate dose and stay there. The full Mounjaro treatment overview covers the licensed strengths and what to expect at each stage.

Side effects are most common after starting or after a dose increase. The profile is GI-led: nausea, loose stools, constipation, indigestion and occasional vomiting are the most frequently reported. They typically ease within days to a couple of weeks as the body adjusts. Dizziness is reported by some people, understanding why Mounjaro can cause dizziness and what to do about it is one of those things patients say they wish they had read beforehand. If you experience severe, persistent stomach pain that radiates toward the back, seek urgent medical attention; this can be a sign of pancreatitis, highlighted by the MHRA in a January 2026 Drug Safety Update for GLP-1 medicines. Suspected side effects can be reported at the MHRA's Yellow Card scheme.

On the question of cost, there is useful context on what Mounjaro actually costs in the UK private market, worth reading before comparing providers, because headline prices vary considerably by dose and by what is or is not included. When you are ready to explore whether treatment is right for you, our prescribers are available through a free consultation, reviewed the same day by a real clinician, not automated software.